Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100013/S032

EXOSEAL Vascular Closure Device

Cordis US Corporation · Decision date Jan 6, 2026

FDA DECISIONP100013/S032

What did the FDA decide?

FDA records P100013/S032 as a supplement to PMA P100013, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 6, 2026.

FDA approval order statement

the addition of an alternate supplier for Exoseal packaging tray components.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jan 6, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P100013/S032
Regulatory pathway
PMA supplement
Product code
MGB
Decision code
OK30
Decision date
Jan 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, hemostasis, vascular.

Product code
MGB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P100013/S032 received

    Application receipt date recorded by FDA.

  2. P100013/S032 · FDA decision

    30-Day Notice

  3. P100013/S033 · Related supplement

    EXOSEAL Vascular Closure Device

  4. P100013/S034 · Related supplement

    Exoseal Vascular Closure Device

Timeline entries are records held by MedtechLedger for P100013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100013

Product / regulatory recordCompanyPathwayDecision dateSource
Cordis US CorporationPMA supplementJan 8, 2026FDA
Cordis US CorporationPMA supplementJun 23, 2026FDA

Explore the linked device profile

Other records with product code MGB

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cordis US Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
14201 NW 60th Ave., Miami Lakes, FL, 33014

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records